文献速递神经肿瘤

弥漫性胶质瘤中端粒酶逆转录酶启动子与IDH突变的灵敏快速检测

Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
PubMed 文献 · Neuro Oncol · 2019-01-01

研究开发了基于等位基因特异性锁定核酸定量PCR的GliomaDx检测方法,可在0.1%突变等位基因分数(对应0.2%肿瘤细胞含量)的分析灵敏度下检测TERTp和IDH1改变;GliomaDx Nest对FFPE样本经预扩增后灵敏度相似;对既往Sanger测序判定为TERTp野生型-IDH野生型的胶质瘤队列检测发现26.3%携带低比例突变。

要点

  • GliomaDx检测TERTp和IDH1改变的分析灵敏度为0.1%突变等位基因分数,对应0.2%肿瘤细胞含量。
  • GliomaDx Nest对预扩增样本检测热点突变的灵敏度与GliomaDx相似,并在临床FFPE样本队列中成功测试。
  • 既往Sanger测序判定为TERTp野生型-IDH野生型的胶质瘤中26.3%携带低比例突变。

核心结论

  • GliomaDx可快速、高灵敏度检测TERTp/IDH突变,识别因其他技术灵敏度不足而可能被漏检的病例。
  • 该方法可能有助于在术中诊断或低肿瘤纯度病例检测等临床场景中对弥漫性胶质瘤样本进行更客观的分类。

研究设计与样本

  • 研究开发了GliomaDx——一种基于等位基因特异性锁定核酸的定量PCR检测方法,用于检测TERTp和IDH突变。
  • 在细胞系DNA和肿瘤百分比不等的冷冻组织弥漫性胶质瘤样本上评估GliomaDx性能,并用微滴数字PCR(ddPCR)和二代测序验证低比例变异。
  • 开发了GliomaDx Nest,在等位基因特异性PCR前加入高保真多重预扩增步骤,用于低输入福尔马林固定石蜡包埋(FFPE)样本。

主要发现

  • GliomaDx检测TERTp和IDH1改变的分析灵敏度为0.1%突变等位基因分数,对应0.2%肿瘤细胞含量。
  • GliomaDx在肿瘤百分比不等的冷冻组织样本队列中识别出所有主要弥漫性胶质瘤组织学类型的TERTp/IDH1改变。
  • GliomaDx Nest对预扩增样本检测这些热点突变的灵敏度相似,并在临床FFPE样本队列中成功测试。
  • 对既往经Sanger测序判定为TERTp野生型-IDH野生型的胶质瘤队列检测显示,26.3%携带低比例突变;ddPCR和全外显子组测序分析确认了这些改变的低突变分数及总体基于突变的肿瘤纯度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in telomerase reverse transcriptase promoter (TERTp) and isocitrate dehydrogenase 1 and 2 (IDH) offer objective markers to assist in classifying diffuse gliomas into genetic subgroups. However, traditional mutation detection techniques lack sensitivity or have long turnaround times or high costs. We developed GliomaDx, an allele-specific, locked nucleic acid-based quantitative PCR assay to overcome these limitations and sensitively detect TERTp and IDH mutations. METHODS: We evaluated the performance of GliomaDx on cell line DNA and frozen tissue diffuse glioma samples with variable tumor percentage to mimic use in clinical settings and validated low percentage variants using sensitive techniques including droplet digital PCR (ddPCR) and next-generation sequencing. We also developed GliomaDx Nest, which incorporates a high-fidelity multiplex pre-amplification step prior to allele-specific PCR for low-input formalin-fixed paraffin embedded (FFPE) samples. RESULTS: GliomaDx detects the TERTp and IDH1 alterations at an analytical sensitivity of 0.1% mutant allele fraction, corresponding to 0.2% tumor cellularity. GliomaDx identified TERTp/IDH1 alterations in a cohort of frozen tissue samples with variable tumor percentage of all major diffuse glioma histologic types. GliomaDx Nest is able to detect these hotspot mutations with similar sensitivity from pre-amplified samples and was successfully tested on a cohort of clinical FFPE samples. Testing of a cohort of previously identified TERTpWT-IDHWT gliomas (by Sanger sequencing) revealed that 26.3% harbored low-percentage mutations. Analysis by ddPCR and whole exome sequencing of these tumors confirmed the low mutant fraction of these alterations and overall mutation-based tumor purity. CONCLUSIONS: Our results show that GliomaDx can rapidly detect TERTp/IDH mutations with high sensitivity, identifying cases that might be missed due to the lack of sensitivity of other techniques. This approach may facilitate more objective classification of diffuse glioma samples in clinical settings such as intraoperative diagnosis or in testing cases with low tumor purity.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Diplas BH, Liu H, Yang R, et al. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Neuro Oncol. 2019. PMID: 30346624. doi:10.1093/neuonc/noy167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。